SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 17 Decipher-focused abstracts will be presented at the ...
CEO Marc Stapley highlighted Q1 revenue of $114.5 million, representing an 18% year-over-year increase. Testing revenue grew 19%, with Decipher and Afirma leading the growth at 33% and 6% respectively ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...
Veracyte, Inc., a leading cancer diagnostics company, today announced that data from its market-leading Decipher Prostate Genomic Classifier are available in a new specialized database that the ...
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About Veracyte: Business Model and Recent Focus Veracyte ...
Veracyte’s VCYT shares have surged 30.9% in the past year, showing impressive momentum. It has significantly outperformed the industry’s 13.1% decline and the S&P 500 composite’s 12.1% gain. Presently ...
Veracyte VCYT shares have surged 45.6% in the past year, showing impressive momentum. It has significantly outperformed the industry’s 7.6% fall and the S&P 500 composite’s gain of 8.8%. Presently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback